- Home
- IMMX vs UCL Comparison
IMMX vs UCL Comparison
Compare IMMX & UCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMMX
- UCL
- Stock Information
- Founded
- IMMX 2014
- UCL 2014
- Country
- IMMX United States
- UCL Hong Kong
- Employees
- IMMX N/A
- UCL N/A
- Industry
- IMMX Medicinal Chemicals and Botanical Products
- UCL Telecommunications Equipment
- Sector
- IMMX Health Care
- UCL Consumer Discretionary
- Exchange
- IMMX Nasdaq
- UCL Nasdaq
- Market Cap
- IMMX 51.1M
- UCL 48.4M
- IPO Year
- IMMX 2021
- UCL 2020
- Fundamental
- Price
- IMMX $1.58
- UCL $1.20
- Analyst Decision
- IMMX Strong Buy
- UCL
- Analyst Count
- IMMX 1
- UCL 0
- Target Price
- IMMX $7.00
- UCL N/A
- AVG Volume (30 Days)
- IMMX 126.0K
- UCL 21.4K
- Earning Date
- IMMX 11-11-2024
- UCL 11-13-2024
- Dividend Yield
- IMMX N/A
- UCL N/A
- EPS Growth
- IMMX N/A
- UCL N/A
- EPS
- IMMX N/A
- UCL 0.12
- Revenue
- IMMX N/A
- UCL $86,076,000.00
- Revenue This Year
- IMMX N/A
- UCL $11.23
- Revenue Next Year
- IMMX $200.00
- UCL $27.52
- P/E Ratio
- IMMX N/A
- UCL $10.82
- Revenue Growth
- IMMX N/A
- UCL 10.63
- 52 Week Low
- IMMX $1.26
- UCL $1.16
- 52 Week High
- IMMX $7.75
- UCL $2.96
- Technical
- Relative Strength Index (RSI)
- IMMX 39.72
- UCL 42.38
- Support Level
- IMMX $1.26
- UCL $1.21
- Resistance Level
- IMMX $1.80
- UCL $1.29
- Average True Range (ATR)
- IMMX 0.15
- UCL 0.07
- MACD
- IMMX -0.01
- UCL -0.00
- Stochastic Oscillator
- IMMX 39.41
- UCL 33.33
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.
About UCL uCloudlink Group Inc.
Ucloudlink Group Inc provides mobile data connectivity and portable WiFi services. The business operates under uCloudlink 1.0, which focuses on cross-border travelers that need mobile data connectivity services across different countries. Under uCloudlink 2.0, provides mobile data connectivity services to local users across different MNOs in a single country. It generates revenue from the provision of data connectivity services, and the sales of terminals and sales of data related products.